Trial Profile
A Safety Study Assessing Oral Anticoagulation With Apixaban Versus Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Phenprocoumon
- Indications Embolism; Stroke
- Focus Adverse reactions
- Acronyms AXADIA
- 06 Nov 2022 Results published in the Circulation
- 26 Sep 2022 Status changed from recruiting to completed.
- 26 Apr 2021 Planned number of patients changed from 79 to 108.